The study tests BNT327, an investigational drug administered via intravenous infusion, in combination with standard chemotherapy drugs like etoposide, carboplatin, paclitaxel, and topotecan. The goal ...

The intervention being tested is BNT327, administered in two dose levels, combined with standard chemotherapy drugs such as etoposide, carboplatin, paclitaxel, and topotecan. The purpose is to ...

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new ...

BNT327/PM8002 has shown encouraging efficacy and tolerability in patients across various tumor types, with more than 700 patients treated in clinical trials to date.

Doctors are looking for ways to improve treatment for NSCLC. In this trial, they are looking at an experimental drug called BNT327. It is a new type of immunotherapy drug . It works in 2 ways. It aims ...

This trial is comparing BNT327 and standard chemotherapy with atezolizumab and standard chemotherapy. It is for people having their first treatment for small cell lung cancer that has spread within ...

BioNTech's BNT327, a next-generation bispecific antibody candidate targeting PD-L1 and VEGF-A, is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to date.

Why it matters: In addition to ongoing clinical trial progress for BNT327, BioNTech was active on the business development ...

Newman’s confidence in BNT327’s prospects justifies his Buy rating on BioNTech SE’s stock. Newman covers the Healthcare sector, focusing on stocks such as Merus, Regeneron, and BioNTech SE.

Multiple registrational trials are planned to start in 2024 and 2025, evaluating BNT327/PM8002 plus chemotherapy in various solid tumor indications, including in patients with small, non-small, and ...

BNT327, BioNTech's PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...